Dr. Elisabeth Roider is a physician-scientist, entrepreneur, and investor at the forefront of the global longevity movement. Trained at Harvard Medical School, the University of Basel, and the University of St. Gallen, she combines 20+ years of experience in medicine, research, and venture building. Her scientific work has been published in top journals, such as Cell, Nature, and The Lancet, and she continues as a group leader at Harvard and Basel University while maintaining her clinical license as as a board-certified dermatologist. She co-founded the longevity company builder Maximon and invested via the Longevity Co-Investment Fund in the space of consumer health, including nutraceuticals, multi-omics diagnostics, walk-in longevity clinics, and a female health platform. She has founded a next-generation skin longevity company and is an active investor in various startups which cover emerging trends, such as algorithm-based vision detection, polygenic risk stratification in fertility medicine, and personalized cancer therapies, while also guiding large funds and corporate VCs on longevity strategies. To close the gap between science and capital, Elisabeth founded the InnoMed Group, offering scientific advisory and an investor club that delivers rigorous diligence, curated deal flow, and syndication in diagnostics, prevention, and biotech. She also created the masterclass Longevity 101 for Investors, translating complex biomedical research into actionable investment strategies. Across all her work, Elisabeth bridges researchers, clinicians, and investors to turn cutting-edge science into credible, scalable ventures that extend not only lifespan but also healthspan.